Ibrance and Mobility decreased - a phase IV clinical study of FDA data

Summary:

Mobility decreased is reported as a side effect among people who take Ibrance (palbociclib), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Letrozole, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Mobility decreased when taking Ibrance. It is created by eHealthMe based on reports of 104,340 people who have side effects when taking Ibrance from the FDA, and is updated regularly.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.

What is Mobility decreased?

Mobility decreased (ability to move is reduced) is found to be associated with 1,774 drugs and 1,632 conditions by eHealthMe. Check the latest studies of Mobility decreased.

On Jul, 19, 2026

104,340 people reported to have side effects when taking Ibrance.
Among them, 285 people (0.27%) have Mobility decreased.

Among these 285 people:

* Approximation only. Some reports may have incomplete information.

Do you take Ibrance and have Mobility decreased?

- Check whether Mobility decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ibrance:

Ibrance (104,434 reports)

Mobility decreased treatments and more:

Mobility decreased (83,538 reports)

How severe was Mobility decreased and when was it recovered:

Mobility decreased in Ibrance

Expand to all the drugs that have ingredients of palbociclib:

Mobility decreased and drugs with ingredients of palbociclib (312 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ibrance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Mobility decreased:

Mobility decreased (1,774 drugs)

Browse all the conditions that are associated with Mobility decreased:

Mobility decreased (1,632 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on palbociclib (the active ingredients of Ibrance) and Ibrance (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.